Compare Cassava Sciences Inc (FLNA) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Under Armour Inc Class A — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Under Armour Inc Class A trades at $5.13 (market cap $2.26B). The key difference: Under Armour Inc Class A is far larger — about 47.3× Cassava Sciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | UA | |
|---|---|---|
Market Cap | $47.75M | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $7.88 |
52-Week Low | $0.87 | $3.96 |
Enterprise Value | -$34.93M | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Under Armour (UA) trades at $5.14, down 9.43% amid bearish technical signals and negative profitability metrics. The company reported Q1 2026 revenue of $1.1 billion, missing expectations, and lowered its fiscal 2027 revenue outlook due to soft consumer demand in North America and Asia-Pacific. Despite beating EPS estimates in two of the last three quarters, negative net income margin of -9.99% and declining revenue trends highlight ongoing challenges.
The stock faces significant headwinds from deteriorating fundamentals and negative cash flow, though analyst consensus remains cautiously optimistic with 38.8% buy ratings. Key risks include continued revenue declines, competitive pressure, and execution challenges in the turnaround strategy. The current valuation at 0.45 P/S offers potential value if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
